Phase III clinical trials in oncology. 20-21 January 2003, London, UKMarc Buyse
International Drug Development Institute, Brussels, Belgium
IDrugs 6:187-90. 2003
Integrating biomarkers in clinical trialsMarc Buyse
International Institute for Drug Development, 30 Avenue Provinciale, 1340 Louvain la Neuve, Belgium
Expert Rev Mol Diagn 11:171-82. 2011
..Contemporary biomarker-based clinical trials in oncology are used as examples...
Progression-free survival is a surrogate for survival in advanced colorectal cancerMarc Buyse
International Drug Development Institute, Louvain la Neuve, Belgium
J Clin Oncol 25:5218-24. 2007
..We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in advanced colorectal cancer...
Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trialsMarc Buyse
From the International Drug Development Institute, Louvain la Neuve, Belgium
Cancer J 15:421-5. 2009
..Data from several meta-analyses suggest that progression-free survival is an acceptable surrogate in advanced colorectal and ovarian cancer, but not in breast and prostate cancer...
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse
International Drug Development Institute, 30 Avenue Provinciale, 1340 Louvain la Neuve, Belgium
Nat Rev Clin Oncol 7:309-17. 2010
..No consensus yet exists on processes or standards for pragmatic evaluation and adoption of biomarkers and surrogate end points in the absence of robust statistical validation...
Generalized pairwise comparisons of prioritized outcomes in the two-sample problemMarc Buyse
International Drug Development Institute, 30 Avenue Provinciale, 1340 Louvain la Neuve, Belgium
Stat Med 29:3245-57. 2010
..We also show that they lead to a general measure of the difference between the groups called the 'proportion in favor of treatment', denoted Δ, which is related to traditional measures of treatment effect for a single variable...
Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemiaMarc Buyse
International Drug Development Institute, Department of Biostatistics, Louvain la Neuve, Belgium
Trials 12:86. 2011
....
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemiaMarc Buyse
International Drug Development Institute, Louvain la Neuve, Belgium
Blood 117:7007-13. 2011
..We conclude that IL-2 alone is not an effective remission maintenance therapy for AML patients in CR1...
Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancerMarc Buyse
ScD, International Drug Development Institute Inc, American Twine Office Park, 222 Third St, Suite 0342, Cambridge, MA 02142, USA
J Clin Oncol 21:1682-7. 2003
..98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves...
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remissionMarc Buyse
International Drug Development Institute, 30 Avenue Provinciale, Louvain la Neuve, Belgium
Haematologica 96:1106-12. 2011
..We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia...
Individual- and trial-level surrogacy in colorectal cancerMarc Buyse
IDDI International Drug Development Institute, Louvain la Neuve, Belgium and Center for Statistics, Hasselt University, Diepenbeek, Belgium
Stat Methods Med Res 17:467-75. 2008
..86. One trial with a large treatment effect on PFS and OS had a strong influence on the results in advanced disease. DFS (and PFS in advanced disease) are acceptable surrogates for OS in colorectal cancer...
Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancerMarc Buyse
International Drug Development Institute, Louvain la Neuve, Belgium
Int J Clin Oncol 14:95-101. 2009
..All of these potential contributions are illustrated with examples in early and advanced colorectal cancer...
Comparison of prognostic gene expression signatures for breast cancerBenjamin Haibe-Kains
Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
BMC Genomics 9:394. 2008
..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms...
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse
International Drug Development Institute, Brussels, Belgium
J Natl Cancer Inst 98:1183-92. 2006
..88 and 0.89, respectively. CONCLUSIONS: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer...
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Clin Cancer Res 13:3207-14. 2007
..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
A unifying approach for surrogate marker validation based on Prentice's criteriaAriel Alonso
Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan Building D, BE 3590 Diepenbeek, Belgium
Stat Med 25:205-21. 2006
..We apply the previous methodology using data from two clinical studies in psychiatry and ophthalmology...
Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpointsAriel Alonso
Center for Statistics, Limburgs Universitair Centrum, Diepenbeek, Belgium
Biometrics 60:724-8. 2004
..We briefly present a hierarchical framework that incorporates ideas from Prentice's work and is uniformly applicable to different types of surrogate and true clinical outcomes...
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic gradeSherene Loi
Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 25:1239-46. 2007
..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
A unified framework for the evaluation of surrogate endpoints in mental-health clinical trialsGeert Molenberghs
I Biostat, Hasselt University, Diepenbeek, Belgium
Stat Methods Med Res 19:205-36. 2010
..Implications for design and for predicting the effect of treatment in a new trial, based on the surrogate, are discussed. A case study in schizophrenia is analysed...
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski
Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
J Clin Oncol 26:1987-92. 2008
....
A perspective on surrogate endpoints in controlled clinical trialsGeert Molenberghs
Center for Statistics, Limburgs Universitair Centrum, Diepenbeek, Belgium
Stat Methods Med Res 13:177-206. 2004
..Clearly statistical evidence should only be seen as a component in a decision making process that also involves a number of clinical and biological considerations...
Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validationTomasz Burzykowski
Center for Statistics, Hasselt University, Agoralaan bldg D, B3590 Diepenbeek, Belgium
Pharm Stat 5:173-86. 2006
..One of its interesting features, apart from providing information relevant to the practical use of a surrogate endpoint, is its natural interpretation from a clinical point of view...
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patientsChristine Desmedt
Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, , Brussels, Belgium
Int J Cancer 119:2539-45. 2006
....
Exploring and validating surrogate endpoints in colorectal cancerTomasz Burzykowski
Center for Statistics, Hasselt University, Agoralaan D, 3590 Diepenbeek, Belgium
Lifetime Data Anal 14:54-64. 2008
..J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years...
Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific timeStuart G Baker
National Cancer Institute, EPN 3131, Bethesda, Maryland 20892 7354, USA
Biometrics 68:248-57. 2012
..To summarize the additional uncertainty from using a predicted instead of true result for the estimated treatment effect, we compute its multiplier of standard error. Software is available for download...
Statistical challenges in the evaluation of surrogate endpoints in randomized trialsGeert Molenberghs
Limburgs Universitair Centrum, TUL, Center for Statistics, Biostatistics, Diepenbeek, Belgium
Control Clin Trials 23:607-25. 2002
..In this paper, we argue that such a multiunit approach should be adopted because it overcomes difficulties that necessarily surround validation efforts based on a single trial. These difficulties are highlighted...
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisChristos Sotiriou
Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
J Natl Cancer Inst 98:262-72. 2006
..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre
Hopital Tenon, Groupe d Etude et de Recherche Clinique en Oncologie Radioitherapie, Paris
J Clin Oncol 21:2896-903. 2003
....
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trialPrudence Francis
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
J Natl Cancer Inst 100:121-33. 2008
..The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel...
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand
, Paris, France
J Clin Oncol 24:394-400. 2006
..4% of these patients. CONCLUSION: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen. Further study is needed to fully evaluate oxaliplatin reintroduction...
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancerAngelo Di Leo
J Clin Oncol 20:1954-5. 2002
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJunichi Sakamoto
Department of Epidemiological and Clinical Research Information Management, Graduate School of Medicine, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
J Clin Oncol 22:484-92. 2004
..The purpose of this meta-analysis is to assess the survival and disease-free survival benefits of treating patients after surgical resection of a primary colorectal tumor with oral fluoropyrimidines for 1 year...
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyChristophe Tournigand
Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France
J Clin Oncol 22:229-37. 2004
..This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B)...
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancerVeronique Dieras
Institut Curie, Department of Medical Oncology, 26 Rue d Ulm, 75005 Paris, France
J Clin Oncol 22:4958-65. 2004
....
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont
Hopital Saint Antoine, Paris Cedex 12, France
J Clin Oncol 25:3224-9. 2007
....
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1Thierry Andre
Public Hôpitaux de Paris and CancerEst, Hopital Tenon, Paris, France
J Clin Oncol 25:3732-8. 2007
....
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancerLaurent Zelek
Department of Medical Oncology, Henri Mondor Hospital, Creteil, France
Expert Rev Anticancer Ther 2:417-25. 2002
..The interested reader can refer to the statistical appendix for details on the methodology used for all meta-analyses...
Progress in the medical treatment of advanced colorectal cancerElizabeth Fabre-Guillevin
Department of Medical Oncology, Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, Creteil, France
Expert Rev Anticancer Ther 3:711-6. 2003
..This review describes the research carried out in this field through randomized trials and meta-analyses aimed at optimizing the efficacy of front-line chemotherapy...
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerAngelo Di Leo
J Clin Oncol 21:2045-7. 2003
Is FOB screening really the answer for lowering mortality in colorectal cancer?Philippe Autier
Centre for Research in Epidemiology CRESIS, Luxembourg Health Institute, Luxembourg, Luxembourg
Recent Results Cancer Res 163:254-63; discussion 264-6. 2003
..Therefore, recommending general population screening with biennial FOBT is still an open question...
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent
North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:8664-70. 2005
..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent
Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 25:4569-74. 2007
..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency...
Statistics in oncologyStephanie R Land
J Clin Oncol 26:3668. 2008
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts
Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
Nat Clin Pract Oncol 3:540-51. 2006
..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment...
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trialsCornelis J A Punt
Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101 6500 HB Nijmegen, The Netherlands
J Natl Cancer Inst 99:998-1003. 2007
..The proposed guidelines may add to the quality and cross-comparability of future studies of adjuvant treatments for cancer...
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart
Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
J Clin Oncol 26:1980-6. 2008
..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival...
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen
Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
JAMA 299:1547-60. 2008
..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
End points in advanced colon cancer clinical trials: a review and proposalCarmen Allegra
University of Florida, Gainsville, FL, USA
J Clin Oncol 25:3572-5. 2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!Laurence Collette
J Clin Oncol 25:5673-4; author reply 5674. 2007
Endpoints and surrogate endpoints in colorectal cancer: a review of recent developmentsPascal Piedbois
Department of Medical Oncology, Henri Mondor Hospital, Creteil, France
Curr Opin Oncol 20:466-71. 2008
..The purpose of this review is to discuss recently published work on endpoints for early and advanced colorectal cancer, as well as the statistical approaches used to validate surrogate endpoints...